Neuroendocrine tumor diagnostics made more precise with new IVDR-certified Chromogranin A CLIA kit.
BioVendor Group launches a new IVDR-certified CLIA kit for quantifying Chromogranin A (CgA), a key biomarker of neuroendocrine tumors. The kit ensures high sensitivity and specificity on the KleeYa® analyzer.
BioVendor Group expands its IVDR-certified portfolio with a new CLIA kit for the detection of Chromogranin A (CgA), a universal biomarker for neuroendocrine tumors. CgA is secreted by all neuroendocrine cells, and its plasma levels correlate with tumor presence and progression. The new kit enables accurate and reliable quantification of CgA in human serum or plasma on the fully automated KleeYa® analyzer. High diagnostic sensitivity and specificity are ensured through the use of recombinant or highly purified native antibodies. The assay is intended for both diagnosis and monitoring of disease progression and treatment response across a broad spectrum of neuroendocrine tumors, including carcinoids, pheochromocytomas, and small cell lung carcinomas.
